Your browser doesn't support javascript.
loading
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers, J S W; Burgers, F H; Terveer, E M; van Leerdam, M E; Korse, C M; Kessels, R; Flohil, C C; Blank, C U; Schumacher, T N; van Dijk, M; Henderickx, J G E; Keller, J J; Verspaget, H W; Kuijper, E J; Haanen, J B A G.
Afiliação
  • Borgers JSW; Department of Medical Oncology, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Burgers FH; Department of Medical Oncology, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Terveer EM; Netherlands Donor Feces Bank, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Leerdam ME; Center for Microbiome Analyses and Therapeutics at Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Korse CM; Department of Gastrointestinal Oncology, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kessels R; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Flohil CC; Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blank CU; Department of Biometrics, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schumacher TN; Department of Pathology, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Dijk M; Department of Medical Oncology, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Henderickx JGE; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Keller JJ; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
  • Verspaget HW; Clinical Trial Service Unit, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kuijper EJ; Center for Microbiome Analyses and Therapeutics at Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Haanen JBAG; Netherlands Donor Feces Bank, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
BMC Cancer ; 22(1): 1366, 2022 Dec 30.
Article em En | MEDLINE | ID: mdl-36585700
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Segunda Neoplasia Primária / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Humans Idioma: En Revista: BMC Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Segunda Neoplasia Primária / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Humans Idioma: En Revista: BMC Cancer Ano de publicação: 2022 Tipo de documento: Article